# US 2023/0053458 A1 · Methods for providing continuous therapy against pnag comprising microbes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053458 A1
- Document ID: US20230053458A1
- Status: Published application
- Kind: A1
- Application number: 17/777,828
- Filed: 2020-11-20
- Published: 2023-02-23
- Earliest claimed: 2019-11-22
- Assignees: Alopexx Inc.
- Applicants: Alopexx, Inc.
- Inventors: Michael WYAND; Gerald F. SWISS
- Web page: https://patentgrep.com/patent/US20230053458A1

## CPC

- A61K 39/02: Bacterial antigens
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61K 39/40: bacterial
- A61P 31/04: Antibacterial agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/627: {characterised by the linker}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are antimicrobial vaccines comprising oligosaccharide β-(1→6)-glucosamine groups.

## Claims

### Claim 1

A method of providing continuous protection against microbial infection, which method comprises administering to said patient a therapeutically effective amount of a monoclonal antibody F-598 and a vaccine of formula I:
(A−B)x−C I
wherein A comprises 3 to 12 β-(1→6)-glucosamine (carbohydrate ligand) groups or mixtures thereof wherein said oligosaccharide portion of the vaccine is represented by formula A:
B is a linker;
where A is as defined above and C is tetatus toxoid;
x is an integer from about 30 to about 39; and
y is an integer from 1 to 10.

### Claim 2 (depends on 1)

The method of claim 1, wherein the vaccine of formula I is administered concurrently with F-598.

### Claim 3 (depends on 1)

The method of claim 1, wherein the vaccine of formula I is administered within about 6 hours of administering F-598.

### Claim 4 (depends on 1)

The method of claim 1, wherein the vaccine of formula I is administered within about 4 hours of administering F-598.

### Claim 5 (depends on 1)

The method of claim 1, wherein the vaccine of formula I is administered within about 2 hours of administering F-598.

### Claim 6 (depends on 1)

The method of claim 1, wherein F-598 is co-administered during an entire treatment period.

### Claim 7 (depends on 1)

The method of claim 1, wherein the linker is represented by the formula:
where A and C are not included within the linker.

### Claim 8 (depends on 1)

The method of claim 1, wherein F-598 is co-administered up until a point where sufficient antibody titer is produced by the vaccine of formula I to effectively treat the patient.

### Claim 9 (depends on 7)

A method for providing effective immunity to a subject from microbes comprising oligosaccharide β-(1→6)-glucosamine groups in their cell wall which method comprises administering the vaccine of claim 7 to said subject.

### Claim 10

A method of inhibiting biofilm formation comprising administering to a patient a therapeutically effective amount of a monoclonal antibody F-598 and a vaccine of formula I:
(A−B)x−C I
wherein A comprises 3 to 12 β-(1→6)-glucosamine (carbohydrate ligand) groups or mixtures thereof wherein said oligosaccharide portion of the vaccine is represented by formula A:
B is a linker;
where A is as defined above and C is tetatus toxoid;
x is an integer from about 30 to about 39; and
y is an integer from 1 to 10.

### Claim 11 (depends on 10)

The method of claim 10, wherein the vaccine of formula I is administered concurrently with F-598.

### Claim 12 (depends on 10)

The method of claim 10, wherein the vaccine of formula I is administered within about 6 hours of administering F-598.

### Claim 13 (depends on 10)

The method of claim 10, wherein the vaccine of formula I is administered within about 4 hours of administering F-598.

### Claim 14 (depends on 10)

The method of claim 10, wherein the vaccine of formula I is administered within about 2 hours of administering F-598.

### Claim 15 (depends on 10)

The method of claim 10, wherein F-598 is co-administered during an entire treatment period.

### Claim 16 (depends on 10)

The method of claim 10, wherein the linker is represented by the formula:
where A and C are not included within the linker.

### Claim 17 (depends on 10)

The method of claim 10, wherein F-598 is co-administered up until a point where sufficient antibody titer is produced by the vaccine of formula I to effectively treat the patient.

### Claim 18 (depends on 16)

A method for providing effective protection against biofilm formed by microbes comprising oligosaccharide β-(1→6)-glucosamine groups in their cell wall which method comprises administering the vaccine of claim 16 to said subject.
